Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Up 98.7% in February

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 30,000 shares, a growth of 98.7% from the February 13th total of 15,100 shares. Based on an average daily volume of 362,000 shares, the short-interest ratio is currently 0.1 days. Approximately 5.4% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bluejay Diagnostics stock. Anson Funds Management LP grew its stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) by 359.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 319,280 shares of the company’s stock after buying an additional 249,770 shares during the quarter. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 at the end of the most recent quarter. 18.47% of the stock is currently owned by institutional investors.

Bluejay Diagnostics Trading Down 0.5 %

Shares of NASDAQ:BJDX opened at $3.98 on Friday. The stock’s 50-day moving average price is $3.77 and its 200-day moving average price is $4.94. Bluejay Diagnostics has a 12-month low of $3.03 and a 12-month high of $349.64. The stock has a market capitalization of $2.20 million, a P/E ratio of 0.00 and a beta of 0.38.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.